By in-depth understanding of the underlining pathology of biological warfare agents, combined with advanced developments of treatment modalities and state-of-the-art antibody engineering, the antibody engineering team develops unique antibody-based solutions for passive-therapy against such pathogens. This well-established platform successfully enabled the isolation of specific, high-affinity and highly efficient human-based antibodies against various warfare agents. The platform can be applied to any biological warfare or infectious disease agents, by tailoring the best immunization strategies and isolating the antibodies with the desired specificities
Immuno-diagnostics based on development of monoclonal and polyclonal antibodies. One-stop-shop for all stages of study from antigen identification and production, through vaccination and all the way to antibody efficacy testing.
Development of highly-sensitive, rapid, accurate and robust antibody-based diagnostic systems for various bacterial and viral pathogens and toxins. These assays are developed to the final product phase, including automation, multiplexing, long-term storage and stabilization and testing under extreme conditions.
Schematic overview of the antibody-development platform. Combinatorial-libraries of antibody-encoding genes derived from hyper-immune animals are screened and high-affinity antibodies are selected.
Schematic representation of the biolayer interferometry-based assay for rapid and highly-sensitive detection of biological warfare agents.